Mace

(redirected from Major Adverse Cardiovascular Events)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.

Mace

A unit of weight in Taiwan approximately equivalent to 3.75 grams. It is used primarily in the sale of bulk foodstuffs.
References in periodicals archive ?
NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced data suggesting that the use of a target low-density lipoprotein particle (LDL-P) number to guide statin therapy in at-risk patients can reduce the risk of major adverse cardiovascular events (MACE) and death, compared to using standard LDL cholesterol (LDL-C) targets as a guide to therapy.
The study, to be completed in June 2017, will be a randomized, double-blind, placebo-controlled trial that will evaluate the effect of long-term treatment with Qsymia on the incidence of major adverse cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death) in obese and overweight people with cardiovascular disease or multiple cardiovascular risk factors.
The primary safety objective is to evaluate the incidence of major adverse cardiovascular events, specifically cardiovascular death, myocardial infarction or stroke.
Positive results on CCTA correlated with major adverse cardiovascular events.
A larger sample size may have either strengthened the provocative results regarding the major adverse cardiovascular events or, alternatively, reduced any evidence of meaningful clinical differences," they wrote (N.
The two primary endpoints of the trial were major bleeding and net adverse clinical events, a composite of major adverse cardiovascular events (death, reinfarction, stroke or ischemic target vessel revascularization) and major bleeding at 30 days.
Patients receiving MABp1 demonstrated a 58 percent reduction in Major Adverse Cardiovascular Events (MACE) and 60 percent longer patency in treated vessels compared to control patients.
Low procedure volume continues to put patients at greater risk for major adverse cardiovascular events in the era of PCI.
The primary endpoint of the Light Study is the time to occurrence of major adverse cardiovascular events (MACE) during randomized treatment for Contrave compared to placebo.
None of the interventions showed any effect on the rates of in-hospital major adverse cardiovascular events or in-hospital mortality, nor did they affect event, read-mission, or death rates over 6 months of follow-up, the investigators noted.
Use of the sirolimus-eluting stent also resulted in a significantly lower rate of major adverse cardiovascular events than did a bare metal stent in the study, known as the Sirolimus-Eluting Stent and a Standard Stent in the Prevention of Restenosis in Small Coronary Arteries Trial (SES-SMART), Dr.
The objective of the trial is to demonstrate that Contrave does not unacceptably increase the risk of major adverse cardiovascular events (MACE).
Full browser ?